A detailed history of Squarepoint Ops LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Squarepoint Ops LLC holds 34,254 shares of VKTX stock, worth $1.45 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34,254
Previous 141,820 75.85%
Holding current value
$1.45 Million
Previous $7.52 Million 71.16%
% of portfolio
0.0%
Previous 0.01%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$49.84 - $70.47 $5.36 Million - $7.58 Million
-107,566 Reduced 75.85%
34,254 $2.17 Million
Q2 2024

Aug 14, 2024

BUY
$47.39 - $80.2 $6.72 Million - $11.4 Million
141,820 New
141,820 $7.52 Million
Q4 2023

Feb 14, 2024

BUY
$9.24 - $19.64 $467,571 - $993,842
50,603 New
50,603 $941,000
Q1 2023

May 15, 2023

BUY
$8.08 - $17.33 $210,589 - $451,671
26,063 New
26,063 $433,000
Q3 2022

Nov 14, 2022

SELL
$2.55 - $3.89 $971 - $1,482
-381 Reduced 2.58%
14,382 $39,000
Q2 2022

Aug 15, 2022

SELL
$2.11 - $3.15 $6,492 - $9,692
-3,077 Reduced 17.25%
14,763 $43,000
Q1 2022

May 16, 2022

SELL
$3.0 - $4.88 $150,837 - $245,361
-50,279 Reduced 73.81%
17,840 $54,000
Q4 2021

Feb 14, 2022

BUY
$4.6 - $6.72 $173,438 - $253,370
37,704 Added 123.97%
68,119 $313,000
Q3 2021

Nov 15, 2021

SELL
$5.58 - $7.04 $383,630 - $484,007
-68,751 Reduced 69.33%
30,415 $191,000
Q2 2021

Aug 16, 2021

SELL
$5.19 - $6.73 $36,791 - $47,708
-7,089 Reduced 6.67%
99,166 $594,000
Q1 2021

May 17, 2021

BUY
$5.74 - $9.67 $355,346 - $598,640
61,907 Added 139.59%
106,255 $672,000
Q4 2020

Feb 16, 2021

SELL
$5.3 - $6.71 $293,280 - $371,304
-55,336 Reduced 55.51%
44,348 $250,000
Q3 2020

Nov 16, 2020

BUY
$5.73 - $8.11 $571,189 - $808,437
99,684 New
99,684 $580,000
Q1 2020

May 15, 2020

SELL
$3.45 - $7.95 $380,697 - $877,258
-110,347 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$6.38 - $8.73 $190,557 - $260,747
29,868 Added 37.11%
110,347 $885,000
Q3 2019

Nov 14, 2019

SELL
$6.55 - $8.6 $361,815 - $475,055
-55,239 Reduced 40.7%
80,479 $554,000
Q2 2019

Aug 14, 2019

BUY
$7.67 - $10.63 $652,855 - $904,804
85,118 Added 168.22%
135,718 $1.13 Million
Q1 2019

May 15, 2019

SELL
$7.58 - $9.94 $192,099 - $251,909
-25,343 Reduced 33.37%
50,600 $503,000
Q4 2018

Feb 14, 2019

BUY
$7.16 - $16.21 $543,751 - $1.23 Million
75,943 New
75,943 $581,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.25B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Squarepoint Ops LLC Portfolio

Follow Squarepoint Ops LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.